ArticleCell2022
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.
Erratum issued Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05683353 (Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors and Discovery of Potential Drug Targets), which is not on this map. Cited by 166 papers.
0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed
25.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors and Discovery of Potential Drug Targets
Who cites it
166 citing papers in PubMed, 257 citations in OpenAlex.
- Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Trial
- Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.Nature communications · 2022Trial
- Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes waved by spike-signature mutations.Emerging microbes & infections · 2026Article
- Predictive markers of SARS-CoV-2 spike-specific cytotoxic T cell activity following Omicron breakthrough infection.Emerging microbes & infections · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Antigenic Variation and Immune Recognition Inference From the COVID-19 Pandemic: An In Silico Comparative Analysis of Spike T Cell Epitopes From the SARS-CoV-2 Variants of Concern.Influenza and other respiratory viruses · 2026Article
- Article
- Mechanisms underlying immunodynamics of layered defenses elicited by mRNA vaccination in children.BMC medicine · 2026Article
- Immunological memory to vaccines.Immunity · 2026Review
- Intranasal immunization with live-attenuated RSV-vectored SARS-CoV-2 vaccines elicits antigen-specific systemic and mucosal immunity and protects against viral challenge and natural infection.bioRxiv : the preprint server for biology · 2026Article
- The genetic basis of the immune response to SARS-CoV-2 infection and vaccination in the Italian municipality of Vo'.Frontiers in immunology · 2026Article
- Association of HLA-B gene polymorphism and blood groups with COVID-19 susceptibility and severity.Scientific reports · 2025Article
- Rice-derived SARS-CoV-2 glycoprotein S1 subunit vaccine elicits humoral and cellular immune responses.Plant biotechnology journal · 2025Article
- Differential reactivity of SARS-CoV-2 S-protein T-cell epitopes in vaccinated versus naturally infected individuals.Clinical & translational immunology · 2025Article
- Bivalent mRNA booster vaccination recalls cellular and antibody immunity against antigenically divergent SARS-CoV-2 spike antigens.NPJ vaccines · 2025Article
- SARS-CoV-2: The Interplay Between Evolution and Host Immunity.Annual review of immunology · 2025Review
- Distinct HLA Haplotypes Are Associated With an Altered Strength of SARS-CoV-2-Specific T-Cell Responses and Unfavorable Disease Courses.European journal of immunology · 2025Article
- Mutational pressure promotes release of public CD8iScience · 2025Article
- Effector CD8 T cell differentiation in primary and breakthrough SARS-CoV-2 infection in mice.Communications biology · 2025Article
- A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity.EBioMedicine · 2025Article
106 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
- Update of
Authors and funding
20 authors at 5 institutions in 2 countries.
Vivek NaranbhaiMassachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa. Electronic address: vnaranbhai@mgh.harvard.edu.
Anusha NathanRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Program in Health Sciences & Technology, Harvard Medical School, Massachusetts Institute of Technology, Boston, MA 02115, USA.
Clarety KasekeRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Cristhian BerriosDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Ashok KhatriMassachusetts General Hospital Endocrine Division and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.
Shawn ChoiMassachusetts General Hospital Endocrine Division and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA.
Matthew A GetzRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Rhoda Tano-MenkaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Onosereme OfomanDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Alton GaytonRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Fernando SenjobeRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Zezhou ZhaoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Program in Health Sciences & Technology, Harvard Medical School, Massachusetts Institute of Technology, Boston, MA 02115, USA.
Kerri J St DenisRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Evan C LamRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Mary CarringtonRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Basic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD 20892, USA.
Wilfredo F Garcia-BeltranRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Alejandro B BalazsRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Bruce D WalkerCenter for the AIDS Programme of Research in South Africa, Durban 4001, South Africa; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; The Broad Institute, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Institute for Medical Engineering and Science, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Gaurav D GaihaRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: ggaiha@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USHarvard University · USMassachusetts General Hospital · USBroad Institute · USCentre for the AIDS Programme of Research in South Africa · ZA
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MTissue Phenotyping CoreP01DK011794 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KRONENBERG, HENRY M., POTTS, JOHN T · 1986 to 2023
$44.4MExploiting Highly Networked CTL Epitopes to Achieve a Functional HIV CureDP2AI154421 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GAIHA, GAURAV DAS · 2020 to 2024
$2.7MEngineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6MUnderstanding and Reversing T Cell Dysfunction to Control and Eliminate Persistent HIV ReservoirsR01AI149704 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2020 to 2024
$2.1MHost genetic resistance to COVID-19ZIABC011949 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2020 to 2025
$997kCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS DP2 AI154421NIAID NIH HHS R01 AI149704NIAID NIH HHS UM1 AI144462NIDA NIH HHS DP2 DA040254NIDDK NIH HHS P01 DK011794NIGMS NIH HHS T32 GM007753
Abstract
The SARS-CoV-2 Omicron variant (B.1.1.529) contains mutations that mediate escape from antibody responses, although the extent to which these substitutions in spike and non-spike proteins affect T cell recognition is unknown. In this study, we show that T cell responses in individuals with prior infection, vaccination, both prior infection and vaccination, and boosted vaccination are largely preserved to Omicron spike and non-spike proteins. However, we also identify a subset of individuals (∼21%) with a >50% reduction in T cell reactivity to the Omicron spike. Evaluation of functional CD4
Indexed as
COVID-19DeltaepitopesHLAneutralizationOmicronSARS-CoV-2T cellvaccinationvariants
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05683353ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.